GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Psyence Biomedical Ltd (NAS:PBM) » Definitions » Inventory-to-Revenue

Psyence Biomedical (Psyence Biomedical) Inventory-to-Revenue : 0.00 (As of Mar. 2023)


View and export this data going back to 2024. Start your Free Trial

What is Psyence Biomedical Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Psyence Biomedical's Average Total Inventories for the quarter that ended in Mar. 2023 was $0.00 Mil. Psyence Biomedical's Revenue for the six months ended in Mar. 2023 was $0.00 Mil.

Psyence Biomedical's Inventory-to-Revenue for the quarter that ended in Mar. 2023 stayed the same from Mar. 2022 (0.00) to Mar. 2022 (0.00)

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.


Psyence Biomedical Inventory-to-Revenue Historical Data

The historical data trend for Psyence Biomedical's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Psyence Biomedical Inventory-to-Revenue Chart

Psyence Biomedical Annual Data
Trend Mar21 Mar22 Mar23
Inventory-to-Revenue
- - -

Psyence Biomedical Semi-Annual Data
Mar21 Mar22 Mar23
Inventory-to-Revenue - - -

Competitive Comparison of Psyence Biomedical's Inventory-to-Revenue

For the Biotechnology subindustry, Psyence Biomedical's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Psyence Biomedical's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Psyence Biomedical's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Psyence Biomedical's Inventory-to-Revenue falls into.



Psyence Biomedical Inventory-to-Revenue Calculation

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Psyence Biomedical's Inventory-to-Revenue for the fiscal year that ended in Mar. 2023 is calculated as

Inventory-to-Revenue (A: Mar. 2023 )
=Average Total Inventories / Revenue
=( (Total Inventories (A: Mar. 2022 ) + Total Inventories (A: Mar. 2023 )) / count ) / Revenue (A: Mar. 2023 )
=( (0 + 0) / 1 ) / 0
=0 / 0
=N/A

Psyence Biomedical's Inventory-to-Revenue for the quarter that ended in Mar. 2023 is calculated as

Inventory-to-Revenue (Q: Mar. 2023 )
=Average Total Inventories / Revenue
=( (Total Inventories (Q: Mar. 2022 ) + Total Inventories (Q: Mar. 2023 )) / count ) / Revenue (Q: Mar. 2023 )
=( (0 + 0) / 1 ) / 0
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Psyence Biomedical  (NAS:PBM) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Psyence Biomedical's Days Inventory for the six months ended in Mar. 2023 is calculated as:

Days Inventory=Average Total Inventories (Q: Mar. 2023 )/Cost of Goods Sold (Q: Mar. 2023 )*Days in Period
=0/0*365 / 2
=

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Psyence Biomedical's Inventory Turnover for the quarter that ended in Mar. 2023 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Mar. 2023 ) / Average Total Inventories (Q: Mar. 2023 )
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Psyence Biomedical Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Psyence Biomedical's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Psyence Biomedical (Psyence Biomedical) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
121 Richmond Street West, Penthouse Suite 1300, Toronto, ON, CAN, M5H 2K1
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed ISO22000 facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Psyence Biomedical (Psyence Biomedical) Headlines